April 30, 2018 - May 3, 2018

Indo US BioTech IPO Review & Recommendations

Dilip Davda has given "May Apply" recommendation to Indo US BioTech IPO.

Indo US BioTech IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	1	0	0	0
%	0.00	100.00	0.00	0.00	0.00

Indo US BioTech IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	May Apply

Indo US BioTech IPO Review by Dilip Davda (May apply)

[Dilip Davda]

Super profits for FY17 and seven months of FY 18 appears to have been window dressed before IPO and are a major concern for its sustainability. Considering this, cash surplus risk savvy investors may consider investment at their own risk for long term.

Read detail review...

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.